

# ECTH 2016

28 - 30 SEPTEMBER 2016

[WWW.ECTH2016.ORG](http://WWW.ECTH2016.ORG)



**ECTH2016**

European Congress on  
Thrombosis and Haemostasis

The Hague, The Netherlands

## SPECIAL FEATURES OF ECTH2016

At ECTH2016 there will be outstanding plenary and State-of-the-Art presentations, oral and poster presentations but also some new items:

### **PhD networking and career lunch**

Where do they go? Universities train students who after their PhD may continue in academia or in other organisations such as government, industry, charitables. Representatives from such organisations will be present at the lunch to chat about how it is to work with them.

### **Science fast and furious**

Introduction-Methods-Results-Discussions in 15 slides. Is there an alternative for the usual presentation form? We found the authors of the.... highest scoring abstracts willing to experiment with new presentation methods, for which they were trained by an expert.

### **Integrated symposia**

Separate worlds? In four invited symposia on different topics we bring together the research in industry and academia, and will see a glimpse of future developments and challenges.

### **Focus symposia**

These symposia consist of presentations of high-scoring submitted abstracts, as do the Oral presentations sessions. However, the first presenter is a seasoned researcher who has been allotted extra time to give a short overview of the research topic of the symposium.



## WELCOME

It is a great pleasure to welcome you to The Netherlands, a country marked by rich cultural heritage and a long and prestigious history of seminal scientific discoveries. Its government seat The Hague is the perfect location to bring together researchers and health professionals from across Europe in the spirit of collaboration, discussion and the translation of science. This first European Congress of Thrombosis and Haemostasis will be an important event for the advancement of Thrombosis and Haemostasis in Europe, and ECTH 2016 will pioneer in the way science will be presented and communicated. In addition to selected abstract presentations, state of the art lectures and plenaries, we will have guided 'TEDx-style' science showcases in the "Science, Fast and Furious" sessions.



We will have our poster sessions, and thematic host areas where you can meet your colleagues to discuss new ideas and future challenges. Being here, you could take the opportunity to enroll in our cultural program to experience a selection of culture and sights that The Hague has to offer. Amongst many highlights the Girl with the pearl earring from Johannes Vermeer will be waiting for you in the "Mauritshuis". We are certain that you will enjoy your time in The Hague and we look forward to seeing you around.

The ECTH Board

## GENERAL FLOORPLAN







## PROGRAMME AT A GLANCE

	KING WILLEM-ALEXANDER	AMAZON	
09.00	<b>EDUCATIONAL SESSION IN COLLABORATION WITH NVTH:</b> How to be a good scientist		
10.30	COFFEE BREAK & POSTER VIEWING		
11.00	<b>EDUCATIONAL SESSION IN COLLABORATION WITH NVTH:</b> Science with a broad view		
12.00	PHD NETWORK & CAREER LUNCH		
13.00	<b>CLOTTING</b> Venous thrombosis	<b>CLOTTING</b> Structure and function	
14.30	COFFEE BREAK & POSTER VIEWING		
15.00	<b>PLENARY</b> Reducing research waste (Malcolm Macleod)		
16.00	<b>SCIENCE, FAST AND FURIOUS</b>		
17.00	<b>OPENING CEREMONY</b>		
17.45	WELCOME RECEPTION		
19.00			

## WEDNESDAY, 28 SEPTEMBER 2016

	MISSISSIPPI	YANGTZE 1 & 2	
			09.00
	COFFEE BREAK & POSTER VIEWING		10.30
			11.00
	PHD NETWORK & CAREER LUNCH		12.00
			13.00
	<b>BLEEDING</b> Experimental models	<b>PLATELETS</b> Mechanisms and regulation	14.30
	COFFEE BREAK & POSTER VIEWING		15.00
			16.00
			17.00
			17.45
	WELCOME RECEPTION		19.00

## PROGRAMME AT A GLANCE

FOYER OF KING WILLEM-ALEXANDER					
MEET THE EXPERTS					
08.30	<b>1</b>  Venous thrombosis treatment	<b>2</b>  Thrombotic thrombocytopenic purpura	<b>3</b>  Haemophilia	<b>4</b>  Atherosclerosis	<b>5</b>  Women disorders
08.55	<b>6</b>  Bleeding disorders	<b>7</b>  Von Willebrand disease	<b>8</b>  Diagnosis of venous thrombosis	<b>9</b>  Thrombophilia	<b>10</b>  Platelets
09.20	SHORT BREAK				
09.30					

**THURSDAY, 29 SEPTEMBER 2016**

FOYER OF KING WILLEM-ALEXANDER					
HOW TO					
	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>
	How to publish?	How to design a clinical study?	How to produce recombinant proteins?	How to switch to long acting products?	How to write a successful grant?
	<b>6</b>	<b>7</b>	<b>8</b>	<b>9</b>	<b>10</b>
	How to design morpholinos?	How to do a GWAS?	How to do population studies?	How to do epitope mapping?	How to study a platelet?
	SHORT BREAK				

## PROGRAMME AT A GLANCE

	KING WILLEM-ALEXANDER	AMAZON	
09.30	<b>VESSEL WALL</b> Mouse models of vessel wall pathology	<b>BLEEDING</b> Regulation of von Willebrand factor by ADAMTS13	
10.30	COFFEE BREAK & POSTER VIEWING		
11.00	<b>STATE OF THE ART</b> (Thomas Renne & Javier Corral)		
12.00	SHORT BREAK		
12.15		<b>SPECIAL SYMPOSIUM</b> <i>(not part of main CME/CPD programme)</i>	
13.15	SHORT BREAK		
13.30	<b>PLENARY</b> Antithrombotic therapy: now and in the future (Harry Büller)		
14.30	<b>VESSEL WALL</b> Endothelial cells	<b>CLOTTING</b> Venous thrombosis and cancer	
15.15	COFFEE BREAK & POSTER VIEWING		
15.45			

## THURSDAY, 29 SEPTEMBER 2016

	MISSISSIPPI	YANGTZE 1 & 2	
			09.30
	<b>CLOTTING</b> New approaches to Identify genetic risk factors for venous thrombosis	<b>PLATELETS</b> Developments in the treatment of thrombotic trombocytopenic purpura	
			10.30
	COFFEE BREAK & POSTER VIEWING		10.30
			11.00
	<b>STATE OF THE ART</b> (Karen Vanhoorelbeke & Meinrad Gawaz)		
			12.00
	SHORT BREAK		12.00
			12.15
		<b>SPECIAL SYMPOSIUM</b> <i>(not part of main CME/CPD programme)</i>	
			13.15
	SHORT BREAK		13.15
			13.30
			14.30
	<b>CLOTTING</b> Inflammation	<b>BLEEDING</b> Diagnosis and prognosis	
			15.15
	COFFEE BREAK & POSTER VIEWING		15.15
			15.45

PROGRAMME AT A GLANCE





## THURSDAY, 29 SEPTEMBER 2016

	MISSISSIPPI	YANGTZE 1 & 2	
			15.45
	<b>VESSEL WALL INVITED INTEGRATED SYMPOSIUM</b> Genetics and complex disease	<b>BLEEDING INVITED INTEGRATED SYMPOSIUM</b> New therapies in Haemophilia	
			17.15

POSTER RECEPTION & POSTER VIEWING

	POSTER SESSIONS					
						17.30
	<b>6</b>	<b>7</b>	<b>8</b>	<b>9</b>	<b>10</b>	
	<b>BLEEDING</b> Conse- quences of bleeding disorders	<b>CLOTTING</b> Regulation and Mecha- nisms	<b>CLOTTING</b> Arterial disease	<b>CLOTTING</b> Venous throm- bosis	<b>CLOTTING</b> Venous thrombosis, cancer and medical conditions	
						18.30

POSTER RECEPTION & POSTER VIEWING

	<b>CONGRESS DINNER AT GEMEENTEMUSEUM</b>					19.30
	(Secure your ticket at the registration desk)					00.00

## PROGRAMME AT A GLANCE

	KING WILLEM-ALEXANDER	AMAZON	
09.00	<b>PLATELETS</b> Clinical aspects	<b>CLOTTING</b> Thrombus formation	
10.00	COFFEE BREAK & POSTER VIEWING		
10.30	<b>STATE OF THE ART</b> (Elisabetta Castoldi & Cecilia Beccattini)	<b>STATE OF THE ART</b> (Peter Collins & Sébastien Lacroix-Desmazes)	
11.30	SHORT BREAK		
11.45	<b>SCIENCE, FAST AND FURIOUS</b>		
12.45	LUNCH BREAK & POSTER VIEWING		
13.45	<b>PLENARY</b> Emerging gene therapy strategies in haemophilia (Thierry Vanden Driessche)		
14.30	<b>CLOSING &amp; ECTH 2018</b>		
15.00			

## FRIDAY, 30 SEPTEMBER 2016

	MISSISSIPPI		09.00
	<b>BLEEDING</b> Haemophilia		10.00
	COFFEE BREAK & POSTER VIEWING		10.30
s)			11.30
	SHORT BREAK		11.45
			12.45
	LUNCH BREAK & POSTER VIEWING		13.45
			14.30
			15.00

POSTER SESSIONS OVERVIEW

POSTER SESSIONS	TOPIC	POSTER BOARD NUMBERS
1	Vessel wall	1 - 6
2	Platelets - regulation and mechanisms	7 - 12
3	Platelets - disease outcomes	13 - 18
5	Bleeding - basic concepts	19 - 24
5	Bleeding - new treatments in haemophilia	25 - 30
6	Consequences of bleeding disorders	31 - 36
7	Clotting - regulation and mechanisms	37 - 42
8	Clotting - arterial disease	43 - 48
9	Clotting - venous thrombosis	49 - 54
10	Clotting - venous thrombosis, cancer and medical conditions	55 - 59

### POSTER PRESENTATIONS

During the poster sessions there is time to discuss with a drink and a snack. Those posters based on the abstracts that were valued highest will be introduced briefly by the authors during the poster presentations.

### POSTER VIEW & DISCUSSION

Take advantage of the coffee breaks to walk around, chat and discuss any of the 210 posters presented in the below four areas.

POSTER VIEW ONLY	TOPIC	POSTER BOARD NUMBERS
	Bleeding	61 - 105
	Clotting	106 - 180
	Platelets	181 - 199
	Vessel Wall	200 - 210

## CME/CPD ACCREDITATION

### ACCREDITATION STATEMENT

#### European Accreditation Council for Continuing Medical Education (EACCME)

The ECTH 2016 European Congress on Thrombosis and Haemostasis is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), [www.uems.net](http://www.uems.net).

The ECTH 2016 European Congress on Thrombosis and Haemostasis is designated for a maximum of (or 'for up to') 15 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

#### American Medical Association (AMA)

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at [www.ama-assn.org/go/internationalcme](http://www.ama-assn.org/go/internationalcme).

#### Royal College of Physicians and Surgeons of Canada

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning

Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. For more information, visit: [www.royalcollege.ca](http://www.royalcollege.ca).

### **CREDIT BREAKDOWN**

Each participant should claim only those hours of credit that he/she actually spent in the educational activity.

<b>Day</b>	<b>Maximum Credits</b>
Wednesday 28 September 2016	6
Thursday 29 September 2016	6
Friday 30 September 2016	3
<b>Total Credits:</b>	<b>15</b>

### **HOW TO RECEIVE YOUR CME/CPD CERTIFICATE**

The CME/CPD certificate will be available after completing the online evaluation survey. The process takes about 5-10 minutes. We thank you in advance for your feedback as it is an important part of the CME/CPD accreditation process which helps improve future educational activities. The CME/CPD certificate will also act as a certificate of attendance.

#### **Before 1 November 2016:**

1. Access the online system by following the link in the email sent to you at the end of the congress.
2. Complete the anonymous online survey.
3. The CME/CPD certificate will be available for download; fill-in and retain for your personal records. In case of questions, please e-mail [info@ecth2016.org](mailto:info@ecth2016.org).

## NETWORKING EVENTS

### WEDNESDAY, 28 SEPTEMBER 2016

- **PhD network & career lunch**

**12.00 – 13.00**

**(Foyer)**

This is a great chance for young doctoral candidates to meet representatives from our sponsors, from government and from various research organisations to discuss how it is to work there. .

- **Opening ceremony & welcome reception**

**17.00 – 19.00**

**(Hall: King Willem-Alexander)**

We invite all delegates of the ECTH 2016 to the official Opening ceremony on Wednesday. You will be treated to a dynamic spectacle of music by the Royal Conservatoire and welcomed by Saskia Middeldorp (Host ECTH 2016 and president NVTH) and Prof. Frits Rosendaal (Board ECTH 2016). Right after, you are welcome to chat and mingle with fellow congress visitors and enjoy a drink along with some delicious bites. Welcome to The Hague!

### THURSDAY, 29 SEPTEMBER, 2016

- **ECTH 5K Run**

**08.00 – 09.00**

**(Starting right outside the ECTH registration area)**

Joining the run is free of charge and you don't need to



register in advance. You will however receive a nice gift when you finish the first ever ECTH 5K Run. Additionally the ECTH Board will donate €10,- per runner to the WakaWaka Foundation, which monitors the responsible and efficient donation of WakaWaka Lights and Powers in humanitarian aid situations in crisis areas like Haiti, Syria, West-Africa, the Philippines and Nepal.

● **Poster reception**

**17.15 – 19.00**

**(Poster Sessions Area)**

Take advantage of the guided sessions - choose the most interesting group and be on time.

● **Congress Dinner**

**19.30 – 00.00**

**(Gemeentemuseum Den Haag)**


Address: Stadhouderslaan 41, 2517 HV, The Hague,  
The Netherlands

**Why:** Don't miss out on the opportunity to network and party with the largest contingent of experts in thrombosis and haemostasis.

Buy your ticket at the registration desk for only €75,-.


**A special treat:** a professional guided tour through the world famous collection of Mondriaan included.

## How to add the app to your start screen



### iOS users

- Open your browser and navigate to:  
**app.twoppy.com/ecth**
- Press the share button
- Select 'Add to Home Screen'
- Press 'Save'



### Android users

- Open your browser and navigate to:  
**app.twoppy.com/ecth**
- Press the settings button
- Press the star symbol in the upper right corner
- Select 'Add to Home Screen'

An abstract graphic design featuring a large, bold red shape on the left and a blue shape on the right, both with white, organic cutouts. The text "OUR PARTNERS" is centered in white on the red background. The entire composition is framed by a thin black border.

**OUR PARTNERS**

## ACKNOWLEDGEMENTS

ECTH wishes to express gratitude to the following companies which, through their generosity, have helped to make this congress possible:



Bristol-Myers Squibb



**CSL Behring**

Biotherapies for Life™



Daiichi-Sankyo



**NOVARTIS**



**ARYOGEN**



Boehringer  
Ingelheim

**GRIFOLS**



A Company of Sysmex Group

**KEDRION**  
BIOPHARMA



Pioneer in Rare Diseases



This activity is supported by an independent educational grant from



Daiichi-Sankyo

The Wi-Fi is generously supported by

**CSL Behring**

Biotherapies for Life™

The congress pens are generously supported by



A Company of Sysmex Group

**NOW APPROVED for:**

- Prevention of stroke and systemic embolism in NVAF
- Treatment of DVT and PE\*
- Prevention of recurrent DVT and PE

## ONCE-DAILY LIXIANA®

Only LIXIANA® combines:

- ✓ Proven efficacy vs. well-managed warfarin<sup>1,2</sup>
- ✓ Superior reduction in major bleeding vs. well-managed warfarin<sup>\*\*1,2</sup>
- ✓ Once-daily dosing across all indications<sup>3</sup>

[www.lixiana.com](http://www.lixiana.com)



Please refer to the SmPC before prescribing, available on [Lixiana.com](http://Lixiana.com) or by scanning the QR code

\* Following initial use of parenteral anticoagulant for at least 5 days.

References: 1. Giugliano RP *et al.* *NEJM* 2013;369(22):2093–2104.

2. The Hokusai-VTE Investigators. *NEJM* 2013;369(15):1406–1415.

3. LIXIANA®, Summary of Products Characteristics, 2015.

NVAF, nonvalvular atrial fibrillation; DVT, deep vein thrombosis; PE, pulmonary embolism.

\*\* The primary safety endpoint for the NVAF trial ENGAGE AF-TIMI 48 was the incidence of adjudicated major bleeding vs. well-managed warfarin.<sup>1</sup> The primary safety endpoint for the VTE trial Hokusai-VTE was the incidence of adjudicated clinically relevant bleeding (composite of major and clinically relevant nonmajor bleeding) vs. well-managed warfarin.<sup>2</sup> Bleeding endpoints were defined based on criteria from the International Society on Thrombosis and Haemostasis.

© 2016 Daiichi Sankyo. All rights reserved. Printed in Europe.



Passion for Innovation.  
Compassion for Patients.™



Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.

With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people.

In addition to its strong portfolio of medicines for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders, the Group's research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics.

For more information, please visit:  
[WWW.DAIICHI-SANKYO.EU](http://WWW.DAIICHI-SANKYO.EU)

## SPECIAL SYMPOSIA

THURSDAY, 29 SEPTEMBER 2016

### ● THE EVOLVING ROLE OF NOACS IN THE MANAGEMENT OF VTE

kindly organised by BMS Pfizer

12.15 – 13.15 (Hall: Amazon)

Chair: Prof. Menno Huisman (The Netherlands)

Initial management of VTE in 2016:

current recommendations

Dr Ander Cohen (United Kingdom)

Duration of treatment in VTE – role of NOACs

Prof. Menno Huisman (The Netherlands)

Outstanding challenges in VTE management

Prof. David Jimenez (Spain)

Q&A

### ● TRANSFORMING THE TREATMENT OF HAEMOPHILIA B

kindly organised by CSL Behring

12.15 – 13.15 (Hall: Yangtze 1&2)

Chair: Michiel Coppens (The Netherlands)

Introducing a new treatment for haemophilia B

Michiel Coppens (The Netherlands)

The revolution in haemophilia B

Alex Veldman (Germany)

Achieving a new standard of care

Claude Négrier (France)

Question and answers

All

Summary and close

Michiel Coppens (The Netherlands)

# The evolving role of NOACs in the management of VTE

## Satellite Symposium


**Thursday, 29th September 2016**  
**12:15 – 13:15**

**Amazon Room**  
World Forum, The Hague

**Menno Huisman** (Chair)  
Netherlands

**Ander Cohen**  
United Kingdom

**David Jiménez**  
Spain



NOACs: non-vitamin K antagonist oral anticoagulants  
VTE: venous thromboembolism

This Satellite Symposium is fully organised and funded by:



Bristol-Myers Squibb



Date of preparation: August 2016 PP-ELI-EUR-0376 PP-ELI-NLD-0085



**Find a good fit for  
your patients**



**Eliquis<sup>®</sup>**  
apixaban

**Join us in the networking  
area and Everest 2.**

Wednesday 28th September 10:00 - 16:00

Thursday 29th September 10:00 - 16:00

Friday 30th September 09:30 - 12:30



**Bristol-Myers Squibb**



Date of preparation: August 2016 Job code: PP-ELI-EUR-0395 PP-ELI-NLD-0097

# TRANSFORMING THE TREATMENT OF HAEMOPHILIA B

## European Congress on Thrombosis and Haemostasis (ECTH)

Thursday 29<sup>th</sup> September 2016, 12:15–13:15

Yangtze 1&2, World Forum, The Hague, The Netherlands

CSL Behring-sponsored satellite symposium at the European Congress  
on Thrombosis and Haemostasis (ECTH) 2016

Lunch will be provided

### Programme

**Chair:** *Michiel Coppens (The Netherlands)*

**12:15** **Introducing a new treatment for haemophilia B**  
*Michiel Coppens (The Netherlands)*

**The revolution in haemophilia B**  
*Alex Veldman (Germany)*

**Achieving a new standard of care**  
*Claude Nègrier (France)*

**Q & A Session**  
*All*

**13:15** **Close of symposium**



**CSL Behring has,  
this year, marked  
100 years of  
delivering on our  
promise to patients.**

And we're just  
getting started.

**[www.cslbehring.com](http://www.cslbehring.com)**

Novartis



## Changing the practice of medicine

At Novartis, we harness the innovation power of science to address some of society's most challenging healthcare issues. Our researchers work to push the boundaries of science, broaden our understanding of diseases and develop novel products in areas of great unmet medical need. We are passionate about discovering new ways to extend and improve patients' lives.



MORE THAN  
**75 YEARS**  
**OF IMPROVING**  
THE HEALTH  
& WELL-BEING  
OF PEOPLE  
WORLDWIDE

**GRIFOLS**

pioneering spirit

Learn more about Grifols at  
[www.grifols.com](http://www.grifols.com)



A Company of Sysmex Group

155, rue d'Eragny,  
95000 Neuville sur Oise, France  
web: [www.hyphen-biomed.com](http://www.hyphen-biomed.com)  
e-mail: [info@hyphen-biomed.com](mailto:info@hyphen-biomed.com)

***Your partner for laboratory assays:***



**Assays for DOACs, Heparins, HIT**



**Assays for Haemophilia Management**

(Chromogenic assays for FVIII:C and FIX activity,  
ELISA for FVIII:C antibodies, Clotting assay for FVIIa activity)



**Customised Assays**

***Experience the innovation,  
experience the difference.***



Lire attentivement les instructions figurant sur l'étiquetage et/ou la notice d'utilisation des réactifs.

■ HYPHEN BioMed (France). \* destination "générique" • Réf\_HBM 014\_v1\_EN • Date de création: 08/2016

# KEDRION

B I O P H A R M A

Kedron Biopharma's commitment to Social Responsibility extends to all the communities we work with, from the sites of our operations to the global environment, from the community of donors to the community of people who use our products.



For more information, please visit: [www.kedron.com](http://www.kedron.com)

## Pioneer in rare diseases

Our history of innovation in haemophilia treatments stretches over 50 years. We have the simple goal to provide people with haemophilia treatment choices that will help them live the lives they want.

Please visit  
[www.sobihaemophilia.com](http://www.sobihaemophilia.com)



Sobi is a trademark of Swedish Orphan Biovitrum AB (publ)  
© 2016 Swedish Orphan Biovitrum AB (publ) – All rights reserved  
Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm, Sweden  
+46(0)8 697 20 00  
Date of preparation: August 2016. PP-1514

 **sobi**  
Pioneer in Rare Diseases

ST **Genesis** *la*



Standardisation



Solution  
intégrale



Automatisation  
complète



Innovation

Bring Haemostasis to light

**Stago**  
At the Heart of Haemostasis

Diagnostic Stago S.A.S.  
RCS Numéro 8305 151 409  
3, allée Thérèse  
92660 Aulnières sur Seine  
France  
Ph. +33 (0)1 46 88 20 20  
Fax. +33 (0)1 47 91 08 91  
webmaster@stago.com  
www.stago.com


L281 - ©2011 Legenda 3 par all rights reserved - November 2011

**ARYOGEN**  
آریوژن فارمد

LIFE CHANGING  
BIOMEDICINES

Established in 2009, AryoGen Pharmed is a biopharmaceutical company specialized in R&D and manufacturing of biosimilar medicinal products. Benefiting from high ranking experts in biopharmaceutical production technologies and with an in-house world class, fully integrated research, development and manufacturing facility, actually AryoGen Pharmed has 4 biosimilars (rFVIIa, Rituximab, Etanercept and Trastuzumab) already marketed in at least one country. In addition, AryoGen Pharmed has started registration of its products in 35 countries worldwide. One of its products, the biosimilar rFVIIa is in development for approval by the European Medicines Agency. AryoGen has more than 250 employees, all involved in manufacturing, controls and R&D, and is rapidly growing. With a strong R&D team developing state-of-the-art technologies, coupled with the company expertise in establishing quality systems, AryoGen is rapidly advancing its pipeline of several other biosimilars.





A BIOPHARMACEUTICAL GROUP

**COMMITTED  
TO LIFE**

OF HUNDREDS OF THOUSANDS OF PATIENTS  
SUFFERING FROM SERIOUS AND OFTEN  
RARE DISEASES WHO ARE TREATED EACH  
YEAR WITH OUR BIOPHARMACEUTICALS.

[www.lfb-group.com](http://www.lfb-group.com)

Follow us on social networks



## ORGANISATIONS REPRESENTED AT THE PHD NETWORK & CAREER LUNCH

Aryogen

BMS Pfizer

CSL Behring

ECTH

Grifols

Hartstichting

Hyphen BioMed

Kedrion

MCI Amsterdam

Ministry of Health, Welfare  
and Sport

Novartis

Stago

Theme: Bleeding

Theme: Clotting

Theme: Platelets

Theme: Vessel wall

Trombosestichting

ZonMW



[illegible]

**NOTES**

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

## NOTES

[illegible]

